SCHEMBL5777907

SCHEMBL5777907

COc1cc(I)c(NC(=O)OC(C)(C)C)c(OC)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 1/20 0.40
CYP1A2 P05177 1/20 0.38
POLB P06746 2/20 0.38
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
GAA P10253 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 1/20 0.36
LCK P06239 3/20 0.36
HPGD P15428 2/20 0.35
TSHR P16473 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HSD17B10 Q99714 2/20 0.35
HTT P42858 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
CTSL P07711 1/20 0.34
TOP2A P11388 1/20 0.34
TOP2B Q02880 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6559448 0.83 ATR (0.50) ATRCYP1A2POLBRAB9ANPC1
SCHEMBL24343974 0.75 CYP1A2 (0.62) ATRCYP1A2GAAKMT2AALDH1A1
SCHEMBL1430094 0.74 ATR (0.38) ATRGAAMEN1KMT2AALDH1A1
SCHEMBL21979959 0.73 LCK (0.43) ATRRAB9ANPC1GAAMEN1
SCHEMBL5820021 0.73 ATR (0.48) ATRRAB9ANPC1GAAMEN1
SCHEMBL6558791 0.73 MAPT (0.52) ATRPOLBRAB9ANPC1GAA
SCHEMBL1430416 0.71 ATR (0.43) ATRRAB9ANPC1GAAMEN1
SCHEMBL24344483 0.71 ALDH1A1 (0.39) ATRCYP1A2RAB9ANPC1GAA
SCHEMBL18016765 0.70 S1PR2 (0.45) ATRCYP1A2RAB9ANPC1GAA
SCHEMBL31550306 0.70 AR (0.42) CYP1A2GAAALDH1A1KDM4ELCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741897-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2014-06-03 US disclosed
US-8741897-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2014-06-03 US disclosed
US-8741897-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2014-06-03 US disclosed
CN-101948425-A As the compound of glucocorticoid ligands, the pharmaceutical composition that comprises them, test kit and preparation method thereof BOEHRINGER INGELHEIM PHARMA 2011-01-19 CN disclosed
CN-1976705-B 1,1, 1-trifluoro-4-phenyl-4-methyl-2- (1H-pyrrolo [2,3-C ] pyridin-2-ylmethyl) pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes BOEHRINGER INGELHEIM PHARMA 2010-09-22 CN disclosed
CN-1976705-A 1,1, 1-trifluoro-4-phenyl-4-methyl-2- (1H-pyrrolo [2, 3-C ] pyridin-2-ylmethyl) pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes BOEHRINGER INGELHEIM PHARMA (US) 2007-06-06 CN disclosed
EP-1673088-A1 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-06-28 EP disclosed
US-20050176706-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-08-11 US disclosed
WO-2005030213-A1 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176706-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof NR3C1, NR3C2, MC2R ATR 2336/4885CYP1A2 727/4885POLB 3055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.